{
	"kj8twdkxText": "Bri<span class=\"_ _0\"></span>nte<span class=\"_ _0\"></span>lli<span class=\"_ _0\"></span>x® i<span class=\"_ _0\"></span>s as ef<span class=\"_ _1\"></span>fica<span class=\"_ _0\"></span>cio<span class=\"_ _0\"></span>us as v<span class=\"_ _2\"></span>enl<span class=\"_ _0\"></span>afaxin<span class=\"_ _0\"></span>e in <br>the tre<span class=\"_ _0\"></span>atme<span class=\"_ _0\"></span>nt of MD<span class=\"_ _0\"></span>D pa<span class=\"_ _0\"></span>tien<span class=\"_ _0\"></span>t<span class=\"_ _1\"></span>s in Asia",
	"kj8twdkyText": "Study Design",
	"kj8twdkzText": "In a randomised, double-blind,<span class=\"_ _0\"></span> 8-week study comparing the efficacy and tolerability of fixed dose treatment with vor<span class=\"_ _0\"></span>tioxetine (10 mg/day) versus venlafaxine extended release <br>tablet (XR) 150 mg/day in major depressive disorder pa<span class=\"_ _0\"></span>tients. The primary endpoint was a change fr<span class=\"_ _0\"></span>om baseline to week 8 in MADRS total score. <span class=\"_ _0\"></span>At week 8, non-inferiority <br>was established with a deference of -1.2 points in favor of vortioxetine (95% CI: -3.0 to 0.6). P<span class=\"_ _0\"></span>atients included in this study were requir<span class=\"_ _0\"></span>ed to have a MADRS total score ≥26 <br>at the baseline visit. <span class=\"_ _0\"></span>The MADRS total score decreased (impr<span class=\"_ _0\"></span>oved) from 32.3+4.6 at baseline to 13.6+9.6 (vortioxetine: n=209) and fr<span class=\"_ _0\"></span>om 32.3+4.5 to 14.8+10.4 (venlafaxine <br>XR:n=215). *MADRS - Montgomery–Åsberg Depression Rating Scale",
	"kj8twdl0Text": "Mean change from baseline",
	"kj8twdl1Text": " in MADRS total score",
	"kj8twdl2Text": "Baseline",
	"kj8twdl3Text": "MADRS&gt;26",
	"kj8twdl4Text": "T<span class=\"_ _2\"></span>reatment week",
	"kj8twdl5Text": "Brintellix® 10mg/day <br>(n=209)",
	"kj8twdl6Text": "V<span class=\"_ _0\"></span>enlafaxine 150 mg/day <br>(n=215)",
	"kj8twdl7Text": "Brintellix® was better tolera<span class=\"_ _0\"></span>ted than venlafaxine as shown by less number of<span class=\"_ _1\"></span> patients who withdrew fr<span class=\"_ _0\"></span>om the <br>study (18.0% versus 27.4%) and less number of adverse events 6.6% versus 13.7%)",
	"kj8twdl8Text": "Study conducted in China,<span class=\"_ _0\"></span> South Kore<span class=\"_ _0\"></span>a, <span class=\"_ _0\"></span>T<span class=\"_ _2\"></span>aiwan and T<span class=\"_ _0\"></span>hailand",
	"kj8twdl9Text": "Estimated change in MADRS total scor<span class=\"_ _0\"></span>es from baseline to W<span class=\"_ _2\"></span>eek 8 ",
	"kj8twdlaText": "(ANCOV<span class=\"_ _2\"></span>A, F<span class=\"_ _2\"></span>AS, L<span class=\"_ _2\"></span>OCF)<span class=\"fs13 v5\">1</span>",
	"Brintellix_47dfd87991": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 25px;\">References</font>\n</span>",
	"Brintellix_4754999406": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>1.</b> Wang G et al. Curr Med Res Opin 2015;31:785-794.\n<br>\n</font>\n</span>",
	"Brintellix_47bee267e3": "Text",
	"Brintellix_47fc96f947": "Text",
	"Brintellix_4700b608bf": "Text",
	"Brintellix_4758f9b284": "Text",
	"Brintellix_47921e05e8": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;color: #4d7f86;\"><span style=\"color: #fff;\">Asian</span>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Elderly&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Working&nbsp;population&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Anhedonia</div>"
}
